Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24O3 |
| Molecular Weight | 288.3814 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](O)[C@@H]2O
InChI
InChIKey=PROQIPRRNZUXQM-ZXXIGWHRSA-N
InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1
| Molecular Formula | C18H24O3 |
| Molecular Weight | 288.3814 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/pro/estradiol.htmlCurator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02906111 | https://www.ncbi.nlm.nih.gov/pubmed/27838536 | https://clinicaltrials.gov/ct2/show/NCT02419729 | https://www.ncbi.nlm.nih.gov/pubmed/26786399 |
Sources: https://www.drugs.com/pro/estradiol.html
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02906111 | https://www.ncbi.nlm.nih.gov/pubmed/27838536 | https://clinicaltrials.gov/ct2/show/NCT02419729 | https://www.ncbi.nlm.nih.gov/pubmed/26786399 |
Estriol (E3), also spelled oestriol, is a steroid, a weak agonist of the estrogen receptors ERα and ERβ., and a minor female sex hormone. According to in vitro study, the relative binding affinity (RBA) of estriol for the human ERα and ERβ was 11.3% and 17.6% of that estradiol, respectively, and the relative transactivational capacity of estrone at the ERα and ERβ was 10.6% and 16.6% of that of estradiol, respectively. Estriol is marketed widely in Europe and elsewhere throughout the world under the brand names Ovestin, Ortho-Gynest, and a variety of others. It is available in oral tablet, vaginal cream, and vaginal suppository form, and is used in menopausal hormone therapy for the treatment of menopausal symptoms. Estriol is also available in some countries as estriol succinate (brand name Synapause), a dosage-equivalent ester prodrug of estriol. Estriol and estriol succinate are not approved for use in the United States and Canada, although they have been produced and sold by compounding pharmacies in North America for use as a component of bioidentical hormone therapy. Estriol can be measured in maternal blood or urine and can be used as a marker of fetal health and well-being. If levels of unconjugated estriol (uE3 or free estriol) are abnormally low in a pregnant woman, this may indicate chromosomal or congenital anomalies like Down syndrome or Edward's syndrome. It is included as part of the triple test and quadruple test for antenatal screening for fetal anomalies.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9357533 |
|||
Target ID: CHEMBL3305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18330978 |
234.42 nM [Kd] | ||
Target ID: CHEMBL2421 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15139751 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Ovestin Approved UseUnknown |
|||
| Primary | Ovestin Approved UseUnknown |
|||
| Primary | Ovestin Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60.57 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
20 μg single, vaginal dose: 20 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
106.4 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
50 μg single, vaginal dose: 50 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
13.77 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
20 μg 1 times / day steady-state, vaginal dose: 20 μg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
22.8 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
50 μg 1 times / day steady-state, vaginal dose: 50 μg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
0.546 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33129232/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
68 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30480330/ |
0.125 mg 1 times / day multiple, vaginal dose: 0.125 mg route of administration: Vaginal experiment type: MULTIPLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
155 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30480330/ |
0.5 mg 1 times / day multiple, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: MULTIPLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
171.65 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
20 μg single, vaginal dose: 20 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
406.75 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
50 μg single, vaginal dose: 50 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
36.33 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
20 μg 1 times / day steady-state, vaginal dose: 20 μg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
73.71 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
50 μg 1 times / day steady-state, vaginal dose: 50 μg route of administration: Vaginal experiment type: STEADY-STATE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2.145 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33129232/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
5643 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30480330/ |
0.125 mg 1 times / day multiple, vaginal dose: 0.125 mg route of administration: Vaginal experiment type: MULTIPLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
18323 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30480330/ |
0.5 mg 1 times / day multiple, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: MULTIPLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
20 μg single, vaginal dose: 20 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26786399/ |
50 μg single, vaginal dose: 50 μg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2.72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33129232/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRIOL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10% |
ESTRIOL serum | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Vulvovaginal burning sensation, vulvovaginal burning sensation... Other AEs: Vulvovaginal burning sensation (9 patients) Sources: vulvovaginal burning sensation (5 patients) Vulvovaginal pruritus (2 patients) Vaginal discharge (1 pt) Vaginal haemorrhage (2 patients) Genital burning sensation (2 patients) Genital swelling (2 patients) Nasopharyngitis (2 patients) Application site pain (3 patients) Nausea (1 pt) Abdominal pain lower (2 patients) Diarrhea (2 patients) Nervous system disorders (1 pt) Skin and subcutaneous tissue disorders (4 patients) Renal and urinary disorders (2 patients) |
0.5 mg 1 times / day steady-state, vaginal Recommended Dose: 0.5 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.5 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 1 pt | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Nervous system disorders | 1 pt | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Vaginal discharge | 1 pt | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Abdominal pain lower | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Diarrhea | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Genital burning sensation | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Genital swelling | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Nasopharyngitis | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Renal and urinary disorders | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Vaginal haemorrhage | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Vulvovaginal pruritus | 2 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Application site pain | 3 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Skin and subcutaneous tissue disorders | 4 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| vulvovaginal burning sensation | 5 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Vulvovaginal burning sensation | 9 patients | 0.2 mg 1 times / day steady-state, vaginal Highest studied dose Dose: 0.2 mg, 1 times / day Route: vaginal Route: steady-state Dose: 0.2 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Use of low potency estrogens does not reduce the risk of hip fracture. | 2002-04 |
|
| Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. | 2002-04 |
|
| Steroid hormone levels during pregnancy and incidence of maternal breast cancer. | 2002-04 |
|
| Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. | 2002-04 |
|
| Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. | 2002-04 |
|
| Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. | 2002-03-22 |
|
| Estradiol, testosterone, dehydroepiandrosterone and androstenedione: novel derivatives and enantiomers. Interactions with rat liver microsomal cytochrome P450 and antioxidant/radical scavenger activities in vitro. | 2002-03-10 |
|
| Information from your family doctor. Triple screening in pregnancy--what it is and what to expect. | 2002-03-01 |
|
| Maternal serum triple analyte screening in pregnancy. | 2002-03-01 |
|
| Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18. | 2002-03 |
|
| Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21. | 2002-03 |
|
| Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. | 2002-03 |
|
| Fetal diaphragmatic hernia and upper limb anomalies suggest Brachmann-de Lange syndrome. | 2002-02 |
|
| Treatment of bitches with acquired urinary incontinence with oestriol. | 2002-01-26 |
|
| A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%. | 2002-01 |
|
| Plasma corticotropin-releasing hormone and unconjugated estriol in human pregnancy: gestational patterns and ability to predict preterm delivery. | 2002-01 |
|
| Accuracy of expected risk of Down syndrome using the second-trimester triple test. | 2002 |
|
| Estradiol valerate/dienogest. | 2002 |
|
| Kinetic comparison of tissue non-specific and placental human alkaline phosphatases expressed in baculovirus infected cells: application to screening for Down's syndrome. | 2002 |
|
| Removal of endocrine-disrupting chemicals in activated sludge treatment works. | 2001-12-15 |
|
| Use of solid-phase extraction in various of its modalities for sample preparation in the determination of estrogens and progestogens in sediment and water. | 2001-12-14 |
|
| Sequential first and second trimester screening tests: correlation of the markers' levels in normal versus Down syndrome affected pregnancies. | 2001-12 |
|
| Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. | 2001-12 |
|
| Unconventional estrogens: estriol, biest, and triest. | 2001-12 |
|
| Identification of negative and positive estrogen response elements in human GnRH upstream promoter in the placental JEG-3 cells. | 2001-11-26 |
|
| A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. | 2001-11 |
|
| Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome. | 2001-11 |
|
| [Health Council of Netherlands recommendation 'Serum screening for risk assessment of Down syndrome for all women' poorly supported]. | 2001-10-20 |
|
| [Influence of hormonal replacement therapy on bacterial vaginosis in the group of peri- and postmenopausal women]. | 2001-10 |
|
| ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). | 2001-10 |
|
| Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women. | 2001-09-28 |
|
| Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. | 2001-09-14 |
|
| [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol]. | 2001-09 |
|
| Effects of 17-beta estradiol and estriol on NMDA-induced toxicity and apoptosis in primary cultures of rat cortical neurons. | 2001-09 |
|
| Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. | 2001-09 |
|
| Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. | 2001-09 |
|
| Mammographic density changes during different postmenopausal hormone replacement therapies. | 2001-09 |
|
| Synthesis of ring B unsaturated estriols. Confirming the structure of a diagnostic analyte for Smith-Lemli-Opitz syndrome. | 2001-08-09 |
|
| Inhibition of large-conductance calcium-activated potassium channel by 2-methoxyestradiol in cultured vascular endothelial (HUV-EC-C) cells. | 2001-08-01 |
|
| Preterm birth risk assessment. | 2001-08 |
|
| Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. | 2001-08 |
|
| Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol. | 2001-08 |
|
| Identification of 16alpha,19-dihydroxyandrostenedione in the serum of pregnant women by gas chromatography-mass spectrometry. | 2001-08 |
|
| An immunoassay for small analytes with theoretical detection limits. | 2001-07-15 |
|
| Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18. | 2001-06 |
|
| Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. | 2001-06 |
|
| Determination of estradiol metabolites in human liver microsome by high performance liquid chromatography-electrochemistry detector. | 2001-04 |
|
| [Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects]. | 2001 |
|
| Multiple marker second trimester serum screening for pre-eclampsia. | 2001 |
|
| Plasma levels and excretion of estrogens in urine in chronic lever disease. | 1975-07 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02906111
1 g/daily of the vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25496649
TNBC cell lines HCC1806, HCC70 and MDA-MB-231 were used for activity evaluation. For stimulation of TNBC cells to analyze signal transduction of GPR30, 4×106 cells were plated in culture medium into 25 cm2 -culture flasks. After attachment, cells were serum starved for 24 hours to synchronize the 17β- estradiol-starved cells in G0-phase. Serum starved cells were treated for 30 minutes either with 10^−4 M estriol or solvent (0.1% ethanol) and subsequently stimulated with 10^−8 M 17β-estradiol in 0.1% ethanol for 10 min or 20 minutes. Cells were harvested and cell pellets lysed in 100 μl Cell lytic M (Sigma, Deisendorf, Germany), supplemented with protease-inhibitor (Sigma, Deisendorf, Germany) and phosphatase-inhibitor (Sigma, Deisendorf, Germany).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:10 GMT 2025
by
admin
on
Mon Mar 31 17:52:10 GMT 2025
|
| Record UNII |
FB33469R8E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2181
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
WHO-ATC |
G03CC06
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
21264-7
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
LOINC |
30510-2
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
43802-8
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
15064-9
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
LOINC |
20466-9
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2249-1
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
LOINC |
14716-5
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
WHO-ATC |
G03CA04
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2251-7
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
INCURIN [AUTHORIZED]
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
CFR |
21 CFR 862.1265
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2250-9
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
LOINC |
27259-1
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
LOINC |
16838-5
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LIVERTOX |
374
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
32353-5
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2248-3
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
14718-1
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
WHO-VATC |
QG03CA04
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
27225-2
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
34293-1
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
13737-2
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
34292-3
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
||
|
WHO-VATC |
QG03CC06
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2252-5
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
21265-4
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
14717-3
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
44004-0
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
CFR |
21 CFR 520.852
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
||
|
LOINC |
2253-3
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
FB33469R8E
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
DTXSID9022366
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
3187
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
1254508
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL193482
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
50-27-1
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
3590
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
C80154
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
12169
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
4094
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB04573
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
5756
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
Estriol (medication)
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
100000092668
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
D004964
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
SUB01971MIG
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
m5032
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
FB33469R8E
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
200-022-2
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
27974
Created by
admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
|
PRIMARY | |||
|
Estriol
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY | |||
|
2821
Created by
admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |